US92337C1045 - Common Stock - After market: 0.69 -0.02 (-2.16%)
NASDAQ:VSTM (2/3/2023, 7:14:50 PM)+0.01 (+0.74%)
|GICS Sector||Health Care|
|Earnings (Last)||11-03 2022-11-03/amc||Earnings (Next)||03-27 2023-03-27/amc|
|Ins Owners||1.55%||Inst Owners||52.46%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. Its advanced product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. VS-6766 is an orally available small molecule RAF/MEK clamp. VS-6766 is a dual RAF/MEK clamp that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.
117 Kendrick St Ste 500
Cambridge MASSACHUSETTS 02494
CEO: Brian M. Stuglik
Verastem Oncology (VSTM) on Tuesday announced a private placement offering of its preferred stock for up to $60M.The company said it had entered into an agreement to sell about 2.1M...
Here you can normally see the latest stock twits on VSTM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.